BACKGROUND: Information regarding growth hormone (GH) therapy in neonatal patients with methylmalonic academia (MMA) is lacking. We present our experience with GH therapy in neonatal patients with MMA. METHODS: Four neonatal patients with mut 0 type MMA were identified through newborn screening for elevated propionylcarnitine (C3) levels. GH therapy (0.6 IU/kg/week, subcutaneously) was prescribed for patient 1 after 1 month of admission, and was prescribed for patients 2, 3 and 4 on the 1st day of admission. We evaluated weight, skin erosion, hospital stay, and serum levels of C3 after GH therapy. RESULTS: All of the neonatal patients with MMA displayed obvious weight gain and distinct improvement in skin erosions after GH therapy. The duration of hospital stay for patients 2, 3 and 4 was reduced compared to that of patient 1. However, the metabolic effects of GH therapy on reducing serum levels of C3 seem to be indeterminate. CONCLUSION: Our clinical findings suggest that GH therapy has potentially beneficial effects on neonatal patients with MMA.
BACKGROUND: Information regarding growth hormone (GH) therapy in neonatal patients with methylmalonic academia (MMA) is lacking. We present our experience with GH therapy in neonatal patients with MMA. METHODS: Four neonatal patients with mut 0 type MMA were identified through newborn screening for elevated propionylcarnitine (C3) levels. GH therapy (0.6 IU/kg/week, subcutaneously) was prescribed for patient 1 after 1 month of admission, and was prescribed for patients 2, 3 and 4 on the 1st day of admission. We evaluated weight, skin erosion, hospital stay, and serum levels of C3 after GH therapy. RESULTS: All of the neonatal patients with MMA displayed obvious weight gain and distinct improvement in skin erosions after GH therapy. The duration of hospital stay for patients 2, 3 and 4 was reduced compared to that of patient 1. However, the metabolic effects of GH therapy on reducing serum levels of C3 seem to be indeterminate. CONCLUSION: Our clinical findings suggest that GH therapy has potentially beneficial effects on neonatal patients with MMA.
Authors: Natalie S Hauser; Irini Manoli; Jennifer C Graf; Jennifer Sloan; Charles P Venditti Journal: Am J Clin Nutr Date: 2010-11-03 Impact factor: 7.045
Authors: Brooke E Kimbrell; Faith Hicks; Cortney B Foster; Omayma A Kishk; Sara A Quinteros-Fernandez; Maria Eleni Nikita; Carol L Greene Journal: Mol Genet Metab Rep Date: 2020-12-13
Authors: Matthias R Baumgartner; Friederike Hörster; Carlo Dionisi-Vici; Goknur Haliloglu; Daniela Karall; Kimberly A Chapman; Martina Huemer; Michel Hochuli; Murielle Assoun; Diana Ballhausen; Alberto Burlina; Brian Fowler; Sarah C Grünert; Stephanie Grünewald; Tomas Honzik; Begoña Merinero; Celia Pérez-Cerdá; Sabine Scholl-Bürgi; Flemming Skovby; Frits Wijburg; Anita MacDonald; Diego Martinelli; Jörn Oliver Sass; Vassili Valayannopoulos; Anupam Chakrapani Journal: Orphanet J Rare Dis Date: 2014-09-02 Impact factor: 4.123
Authors: Parham Habibzadeh; Zahra Tabatabaei; Mohammad Ali Farazi Fard; Laila Jamali; Aazam Hafizi; Pooneh Nikuei; Leila Salarian; Mohammad Hossein Nasr Esfahani; Zahra Anvar; Mohammad Ali Faghihi Journal: BMC Med Genet Date: 2020-02-03 Impact factor: 2.103